The Canadian federal government wishes to implement the Comprehensive Economic and Trade Agreement (“CETA”) after it was signed at the end of October 2016. Bill C-30 seeks to amend the Patent Act to provide for the issuance of Certificates of Supplementary Protection (“CSP”), which seeks to compensate patentees for the effective loss of patent protection they suffer as they await regulatory approval to market a drug in Canada.